FOLH1 and posterior cortical atrophy: Consistent with clinical findings from other groups 7, 9, we found that PSMA radioligand therapy prolonged the survival time for patients with primary PCa and lymph node (LN) mPCa, but was limited for patients with bone mPCa in our cohort (Figure S1A).